Phocas Financial Corp. Sells 71,215 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Phocas Financial Corp. reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 85.0% during the fourth quarter, HoldingsChannel reports. The firm owned 12,549 shares of the medical equipment provider’s stock after selling 71,215 shares during the quarter. Phocas Financial Corp.’s holdings in Lantheus were worth $1,123,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of LNTH. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the last quarter. State of New Jersey Common Pension Fund D grew its holdings in Lantheus by 0.4% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after buying an additional 115 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in shares of Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 129 shares during the last quarter. UMB Bank n.a. boosted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus during the 3rd quarter valued at $25,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $80.07 on Wednesday. The firm has a fifty day moving average price of $89.77 and a 200-day moving average price of $96.81. Lantheus Holdings, Inc. has a 1 year low of $56.44 and a 1 year high of $126.89. The stock has a market cap of $5.57 billion, a PE ratio of 13.32 and a beta of 0.44.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Insiders Place Their Bets

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.